Cancer Gene Therapy Market Analysis | 2022-2028

“The Cancer Gene Therapy Market was estimated at US$ 1.23 billion in 2021 and is expected to grow at a CAGR of 18.3% during 2022-2028 to reach US$ ~11.9 billion in 2028”.

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Cancer gene therapy is an innovative medical approach that uses genetic material to treat or prevent cancer. It involves modifying or repairing genes within cancer cells to inhibit their growth induce cell death, or enhance the body's immune response to target cancer cells.

This promising field aims to provide more precise and less invasive treatment options, with the potential for fewer side effects compared to traditional treatments like chemotherapy and radiation therapy. Researchers are continually developing and testing gene therapy techniques to combat various types of cancer, offering new hope for patients in the fight against this devastating disease.

Market Drivers

The market's expansion is linked to elements including the rising demand for gene therapy and the rise in cancer incidences worldwide. Additionally, it is projected that gene therapy will develop into an efficient alternative treatment for all malignancies and neoplastic illnesses with the development of advancements in the field.

A considerable need for novel therapeutic medications that might be useful for cancer therapy is anticipated due to the rising incidence of cancer cases. Conventional gene treatments now target the immune system to improve remissions for patients with advanced-stage tumours due to the rising role of immunotherapy in cancer treatment.

For instance, the Hadassah Cancer Research Institute (HCRI), Jerusalem, announced in September 2022 that it will serve as the CancerRNA's leader. CancerRNA is a global forum devoted to the development and use of RNA-based immunotherapy to successfully harness anti-cancer immune responses.

Cancer was the second-leading cause of death globally in 2018, according to the World Health Organization, and it took almost 9.6 million lives. Around the world, cancer is responsible for 1 in 6 fatalities. Due to this market circumstance, the global market for cancer gene therapy is rapidly growing.

For the forecast period, it is also anticipated that increasing R&D investments, rising demand for DNA vaccines, improving regulatory standards regarding the quality of products used in gene therapy, and ethical acceptance of gene therapy treatments for cancer will spur the growth of the global cancer gene therapy market.

The global market for cancer gene therapy is expanding as a result of increased rates of lifestyle diseases including diabetes and obesity, rising health-care spending, and the quickly expanding diagnostic sector. Additionally, the market for cancer gene therapy is being propelled forward by the aging population, rising demand for laboratory automation, and increased awareness of preventative healthcare.

The high cost of gene therapy and unfavorable immune reactions are anticipated to slow the market's expansion for cancer gene therapy. The market will be challenged by the absence of healthcare infrastructure in developing nations.

Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

• The substantial research and development tactics used by biopharmaceutical companies for the creation of novel therapeutic medications are another factor contributing to the market's expansion. For greater market penetration, top market companies are concentrating on R&D and regional growth tactics. For instance, in August 2022, the FDA approved Bluebird Bio's BLUE.O gene therapy for use in the treatment of patients with a rare condition that needs routine blood transfusions. Each unit of the medication costs USD 2.8 million.

Recent Developments

The market participants are actively pursuing partnerships, growth, acquisitions, and significant financial investments to develop gene therapy research and provide new therapeutic medications for the treatment of various malignancies.

For instance:

• In April 2022, GlaxoSmithKline plc announced the acquisition of Sierra Oncology for USD 55 per share with a total equity value of USD 1.9 billion to accelerate the therapeutic research on uncommon kinds of cancer.
• In January 2022, Ori Biotech Ltd. announced that it has raised more than USD 100 million in a Series B fundraising round. The money will be used to hire more key employees to help the company launch its cutting-edge cell and gene therapy manufacturing platform.
• In March 2021, The U.S. FDA authorized Abecma (idecabtagene vicleucel) as a cell-based gene therapy for the treatment of multiple myeloma patients who failed to respond to the first lines of therapy.
• In October 2020, Orca-T (produced by Orca Bio) was permitted to utilize RMAT on patients with blood malignancies.
• In July 2020, PRIME was given to Adaptimmune to utilize ADP-A2M4 transduced CD4+ and CD8+ cells for the treatment of HLA-A positive patients with metastatic synovial sarcoma.

Segments Analysis

By Therapy Type

“The gene-induced immunotherapy dominated the market in 2021”.

The market is segmented into oncolytic virotherapy, gene-induced immunotherapy, and gene transfer. In 2021, the market was led by gene-induced immunotherapy. The research investigations that seek to improve the immune system's ability to fight off infection are to blame for the segment's supremacy.

Numerous cancer gene treatments are created using immunotherapy components as a foundation. For instance, the autologous cellular immunotherapy PROVENGE (offered by Dendreon Corporation) is intended to activate a patient's immune system against prostate cancer.

Due to its high degree of efficacy and favorable outcomes, oncolytic virotherapy is anticipated to expand at the quickest rate over the projection period. By activating natural killer cells, oncolytic viruses can kill cancer cells without harming nearby healthy cells. Additionally, there is attractive research funding available for oncolytic virotherapy.

For example, the National Institutes of Health granted the researchers at the University of Houston's Center for Nuclear Receptors and Cell Signaling a USD 1.8 million grant in July 2022 to study oncolytic virotherapy.

By End-User Type

“The biopharmaceutical businesses segment dominated the market in 2021”.

The cancer gene therapy market has been divided into research institutes, biopharmaceutical companies, diagnostic centers, and others. In 2021, the biopharmaceutical businesses segment dominated the market.

This is explained by the rising incidence of numerous cancer kinds worldwide as a result of multiple inherited, environmental, and lifestyle risk factors. Additionally, the industry is stimulated by the growing use of fundamental gene therapy choices by biopharmaceutical behemoths to create cancer treatment plans.

Numerous novel therapeutic medications are through various stages of testing, and businesses are working hard to commercialize them in various parts of the world. For instance, Bluebird Bio, Inc. introduced ZYNTEGLO, a one-time gene therapy treatment, in Germany in January 2020 for patients 12 years of age and older.

Regional Analysis

“North America held the largest market share in 2021”.

The market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In terms of region, North America had the largest share in 2021. The National Cancer Institute and the government have created a supportive environment to encourage research and development efforts to improve cancer medicines, which is credited for this.

Additionally, the market in the region is growing as a result of the presence of major market players therein, their research into developing gene therapy for the treatment of cancer, and their cooperative efforts to advance research. For instance, Merck & Co., Inc., and Orna Therapeutics Inc. partnered in August 2022 to find, develop, and commercialize several programmes, including the use of mRNA for cancer gene therapy.

Due to increased government support for novel therapeutic research and rising demand for new therapies that could assist in addressing the region's rising incidence of cancer cases, Europe is anticipated to see the fastest growth throughout the projection period.

Additionally, the "Horizon Europe Mission on Cancer" of the European Union was established in September 2021 to provide funding for a wide range of initiatives aimed at reducing the incidence of cancer in Europe by promoting research and innovation in cancer therapies. By 2030, the project is expected to assist more than 3 million cancer survivors.

Want to know which region offers the best growth opportunities? Register Here

Key Players

The following are the key players in the Cancer Gene Therapy Market (arranged alphabetically)

• Abeona Therapeutics Inc.
• Altor Bioscience Inc.
• Asklepios BioPharmaceutical Inc.
• BioCancell Inc.
• Bluebird Bio Inc.
• CelgeneInc.
• Elevate BioInc.
• Genelux Corporation
• GenVec
• GlaxoSmithKlineInc.
• Introgen TherapeuticsInc.
• MerckKGaA
• OncoGenex Pharmaceuticals Inc. 

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.